EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies

Yonghyo Kim, Viktória Doma, Uğur Çakır, Magdalena Kuras, Lazaro Hiram Betancourt, Indira Pla, Aniel Sanchez, Yutaka Sugihara, Roger Appelqvist iD, Henriett Oskolas, Boram Lee, Jéssica Guedes und 18 weitere

Cancer · 2025

DOI: 10.1002/cncr.35897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Yonghyo Kim und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Melanoma, Proteome, Mitochondria, Skin Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Fru Berta Kamprads Stiftelse, Crafoordska Stiftelsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma, the deadliest form of skin cancer, exhibits resistance to conventional therapies, particularly in advanced and metastatic stages. Mitochondrial pathways, including oxidative phosphorylation and mitochondrial translation, have emerged as critical drivers of melanoma progression and therapy resistance. This study investigates the mitochondrial proteome in melanoma to uncover novel therapeutic vulnerabilities.

Methods

Quantitative proteomics was performed on 151 melanoma‐related samples from a prospective cohort and postmortem tissues. Differential expression analysis identified mitochondrial proteins linked to disease aggression and treatment resistance. Functional enrichment analyses and in vitro validation using mitochondrial inhibitors were conducted to evaluate therapeutic potential.

Results

Mitochondrial translation and oxidative phosphorylation (OXPHOS) were significantly upregulated in aggressive melanomas, particularly in BRAF‐mutant and metastatic tumors. Inhibition of mitochondrial pathways using antibiotics (doxycycline, tigecycline, and azithromycin) and OXPHOS inhibitors (VLX600, IACS‐010759, and BAY 87‐2243) demonstrated dose‐dependent antiproliferative effects in melanoma cell lines, sparing noncancerous melanocytes. These treatments disrupted mitochondrial function, suppressed key metabolic pathways, and induced apoptosis, highlighting the clinical relevance of targeting these pathways.

Conclusions

This study reveals mitochondrial pathways as critical drivers of melanoma progression and resistance, providing a rationale for targeting mitochondrial translation and OXPHOS in advanced melanoma. Combining mitochondrial inhibitors with existing therapies could overcome treatment resistance and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProteomeMitochondriaSkin NeoplasmsMitochondrial ProteinsHumansOxidative PhosphorylationCell Line, TumorProteomicsFemaleApoptosisMaleProto-Oncogene Proteins B-rafProspective StudiesCell ProliferationDrug Resistance, NeoplasmMiddle Aged

Stichwörter der Autor:innen

BRAF mutationMCM complexmelanomamitochondrial metabolismmitochondrial proteomemitoribosomesoxidative phosphorylationproteomics

Substanzen

ProteomeMitochondrial ProteinsProto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Therapeutics and Biotechnology Division, Data Convergence Drug Research Center, Korea Research Institute of Chemical Technology (KRICT), Daejeon, Korea.
  • Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
  • Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
  • Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Lund, Sweden.
  • Department of Biomedical Engineering, Clinical Protein Science & Imaging, Lund University, Lund, Sweden.

ORCID-Profile: Roger Appelqvist, Jeovanis Gil

Förderung

  • National Research Foundation of Korea
  • Fru Berta Kamprads Stiftelse
  • Crafoordska Stiftelsen

Zitieren

APA

Kim, Y., Doma, V., Çakır, U., Kuras, M., Betancourt, L. H., Pla, I., Sanchez, A., Sugihara, Y., Appelqvist, R., Oskolas, H., Lee, B., Guedes, J., Monnerat, G., Carneiro, G. R. A., Nogueira, F. C. S., Domont, G. B., Malm, J., Baldetorp, B., Wieslander, E., …, & Gil, J. (2025). Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies. Cancer. https://doi.org/10.1002/cncr.35897

Vancouver

Kim Y, Doma V, Çakır U, Kuras M, Betancourt LH, Pla I, et al. Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies. Cancer. 2025. doi:10.1002/cncr.35897

BibTeX
@article{Kim2025,
  author = {Kim, Yonghyo and Doma, Viktória and Çakır, Uğur and Kuras, Magdalena and Betancourt, Lazaro Hiram and Pla, Indira and Sanchez, Aniel and Sugihara, Yutaka and Appelqvist, Roger and Oskolas, Henriett and Lee, Boram and Guedes, Jéssica and Monnerat, Gustavo and Carneiro, Gabriel Reis Alves and Nogueira, Fábio C S and Domont, Gilberto B and Malm, Johan and Baldetorp, Bo and Wieslander, Elisabet and Németh, István Balázs and Szász, A Marcell and Hong, Runyu and Pawłowski, Krzysztof and Rezeli, Melinda and Kwon, Ho Jeong and Timar, Jozsef and Fenyö, David and Kárpáti, Sarolta and Marko-Varga, György and Gil, Jeovanis},
  title = {Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35897}
}
Kostenlos starten →